FIBROCELL SCIENCE, INC. (NASDAQ:FCSC) Files An 8-K Other EventsItem 8.01 Other Events.
On May 18, 2018, Fibrocell Science, Inc. posted an updated Corporate Presentation disclosing interim results and progress of its Phase 1/2 clinical trial of FCX-007 on its website at www.fibrocell.com. A copy of the presentation is filed herewith as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
Corporate Presentation dated May 18, 2018.
Fibrocell Science, Inc. ExhibitEX-99.1 2 a051818fcsciidpresfinalv.htm EXHIBIT 99.1 a051818fcsciidpresfinalv FCX-007 Interim Data Update Forward-Looking Statements This presentation and our accompanying remarks contain “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements that are not historical facts are hereby identified as forward- looking statements for this purpose and include,…To view the full exhibit click
About FIBROCELL SCIENCE, INC. (NASDAQ:FCSC)
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.